Repotrectinib

Chemical formula: C₁₈H₁₈FN₅O₂  Molecular mass: 355.144 g/mol  PubChem compound: 135565923

Active ingredient description

Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC. Fusion proteins that include ROS1 domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Repotrectinib exhibited anti-tumor activity in cultured cells expressing ROS1 fusions and mutations including SDC4-ROS1, SDC4-ROS1G2032R, CD74-ROS1, CD74-ROS1G2032R, CD74-ROS1D2033N, and CD74-ROS1L2026M.

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
AUGTYRO Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

DrugBank Drug: DB16826
KEGG Drug: D11454
PubChem Compound: 135565923
RxNorm Ingredient: 2670644
UNII Identifier: 08O3FQ4UNP
REPOTRECTINIB

Medicines

Repotrectinib is an active ingredient of these brands:

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈